Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Strategies for Preventing and Managing Treatment Related Neutropenia

October 17th 2025

Panelists discuss how neutropenia management varies widely across institutions, with some using primary prophylaxis with G-CSF or trilaciclib, while others tailor supportive care based on individual patient risk factors including age, comorbidities, and prior treatment tolerance.

Unmet Needs to Address in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss unmet needs in advanced NSCLC.

Novel Biomarkers to Watch in Advanced NSCLC

October 16th 2025

Julia Rotow, MD, and Jyoti Malhotra, MD, MPH, discuss novel biomarkers under investigation in advanced NSCLC.

Dr Perol on Unmet Need for Post Immunotherapy Strategies in Lung Cancer

October 16th 2025

Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.

Dr Peters on the Importance of Consensus Meetings to Address Clinical Ambiguity in Lung Cancer

October 16th 2025

Solange Peters, MD, PhD, discusses the necessity of global consensus meetings to navigate clinical "gray zones" in lung cancer management.

Dr Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC

October 16th 2025

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Dr Le on the Efficacy of Firmonertinib for the Treatment of EGFR PACC–Mutated NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Dr Le on the Prevalence of EGFR PACC Mutations in NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Dr Lee on the Role of IMRT in Locally Advanced NSCLC Management

October 14th 2025

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

‘Google Maps’ Approach to Revolutionize Lung Cancer Treatment

October 14th 2025

Researchers developed a way to predict how lung cancer cells will respond to different therapies, allowing for more effective individualized treatment.

Managing Early-Stage NSCLC Post Neoadjuvant Therapy in Patients Who Are Not Surgery Candidates

October 14th 2025

Panelists discuss how to pivot treatment plans when patients cannot proceed to surgery after induction therapy, emphasizing the importance of determining resectability up front and having multidisciplinary contingency plans.

Surgical Decision-Making: Resectable vs Borderline Resectable NSCLC

October 14th 2025

Panelists discuss how resectability determination remains surgeon-dependent and institution-specific, requiring careful consideration of both technical feasibility (“can you”) and appropriateness (“should you”) for individual patients.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews

October 13th 2025

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

Navigating Immunotherapy in Advanced NSCLC After Early-Stage IO Therapy

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

5-Year EMPOWER-Lung 3 Data for Cemiplimab Plus Chemo in Advanced NSCLC

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Practical Approaches to Immune-Related Adverse Events in SCLC

October 10th 2025

Panelists discuss how monitoring for long-term immunotherapy toxicities requires regular imaging and symptom assessment, with early recognition and treatment of pneumonitis, hypothyroidism, and adrenal insufficiency being critical for maintaining patients on therapy and preventing chronic complications.

Managing Toxicity With Combined Chemoradiation and Immunotherapy

October 10th 2025

Panelists discuss how managing toxicities during chemoradiation requires proactive counseling about esophagitis and fatigue, while immunotherapy consolidation typically doesn’t enhance these acute toxicities, making it feasible to start within the recommended timeframe after completion of chemoradiation.

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

October 8th 2025

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma

October 8th 2025

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.